Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology, Inc. (CSBR) has announced a new therapeutic co-development partnership with Fannin Innovation Studio. This collaboration aims to combine Champions' Lumin platform with Fannin's Raptamer platform to create next-generation Raptamer Drug Conjugates (RDCs), specifically targeting tumors such as non-small cell lung cancer and head and neck cancer. The partnership will share ownership of developments and initiate a joint venture after meeting specific milestones. The collaboration harnesses AI-driven analytics and unique platforms to expedite clinical evaluation of novel therapeutic targets.
Champions Oncology (Nasdaq:CSBR) and Alloy Therapeutics have announced a new partnership aimed at developing therapeutic monoclonal antibodies for use in next-generation Antibody Drug Conjugates (ADCs). The collaboration will leverage Champions' Lumin platform for innovative drug discovery, focusing initially on a target linked to hematologic tumors such as Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). Champions will retain ownership of the developed therapeutic molecule, while Alloy will receive milestone and royalty payments.
Champions Oncology, a global biotech leader, reported a record revenue of $11.8 million for Q2 of fiscal 2022, marking a 17% year-over-year increase.
The company posted a net income from operations of $263,000 and a non-GAAP income of $743,000. Gross margin improved to 52%, driven by reduced reliance on outsourcing.
R&D expenses surged by 39.3% to support new therapeutic targets, while sales and marketing costs rose by 21.7%. The company ended the quarter with a solid cash position of $4.8 million.
Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter ended October 31, 2021, on December 13, 2021, after market close. A conference call is scheduled for the same day at 4:30 P.M. EST to discuss the results. Interested participants can join the call via specific dial-in numbers provided in the release. Champions Oncology is known for its transformative technology solutions in oncology drug discovery and development, focusing on data-driven research methodologies.
Champions Oncology (NASDAQ:CSBR) has opened a new laboratory in Bresso, Italy, located near Milan, as part of its global expansion strategy. This facility aims to enhance its biomarker services, which have seen significant growth since their introduction in 2019. The OpenZone Life Sciences Campus, where the lab is situated, is undergoing major expansion with an investment of approximately 65 million euros. This move is expected to provide quicker access to clinical trial patient samples, positioning Champions to serve clients in the European biotech and pharmaceutical markets more effectively.
Champions Oncology (CSBR) reported record revenue of $11.3 million for Q1 FY2022, marking an 18% increase year-over-year. The company achieved a non-GAAP income of $422,000, while operational losses were $175,000, impacted by increased R&D expenses. Total costs rose 20% to $11.4 million. Gross margins improved to 52% due to internalizing lab work. The firm continues to expand its Software as a Service (SaaS) offerings and therapeutic target discovery initiatives, ending the quarter with a solid cash position of $4 million.
Champions Oncology, Inc. (CSBR) is set to announce its financial results for the first quarter ending July 31, 2021, on September 13, 2021, after market close. A conference call will be held at 4:30 P.M. EDT to discuss these results. Interested parties can join via phone or access a replay within 72 hours on the company's website. Champions Oncology is recognized for its transformative technology solutions in oncology drug discovery and development, utilizing advanced research and experimental tools.
Champions Oncology (NASDAQ: CSBR) has expanded its corporate strategy to enter the drug discovery and development space, enhancing its oncology technology solutions. The company operates three business units: the Research Services Business, the Research Software Business featuring Lumin Bioinformatics, and the newly launched Discovery and Innovation Business. This strategic move is based on a unique dataset derived from a 'living tumor bank', allowing for improved drug response insights and therapeutic target discovery using advanced computational methods.
Champions Oncology (NASDAQ:CSBR) reported record annual revenue of $41 million for the fiscal year ending April 30, 2021, marking a 28% year-over-year growth. The fourth quarter alone saw revenue rise by 21% to $10.6 million. Significant investments in research, development, and new service capabilities contributed to an operating income of $2.1 million, reversing prior losses. The company's gross margin improved to 48%. Despite a net cash use of $1.7 million for the year, the company ended with $4.7 million in cash and no debt.
Champions Oncology (NASDAQ:CSBR) will release its fourth quarter financial results on July 22, 2021, before market open. The company specializes in oncology technology solutions aimed at enhancing drug discovery through advanced pharmacology, biomarker, and data platforms. A conference call will follow on the same day at 8:30 a.m. EDT to discuss the financial results. Stakeholders can join by calling 877-407-8035. A recording of the call will be available post-event.